JP5695075B2 - アルツハイマー病又は軽度認知症のバイオマーカー - Google Patents
アルツハイマー病又は軽度認知症のバイオマーカー Download PDFInfo
- Publication number
- JP5695075B2 JP5695075B2 JP2012539625A JP2012539625A JP5695075B2 JP 5695075 B2 JP5695075 B2 JP 5695075B2 JP 2012539625 A JP2012539625 A JP 2012539625A JP 2012539625 A JP2012539625 A JP 2012539625A JP 5695075 B2 JP5695075 B2 JP 5695075B2
- Authority
- JP
- Japan
- Prior art keywords
- blood
- candidate substance
- level
- desmosterol
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims description 213
- 206010012289 Dementia Diseases 0.000 title claims description 195
- 239000000090 biomarker Substances 0.000 title description 21
- 239000008280 blood Substances 0.000 claims description 373
- 210000004369 blood Anatomy 0.000 claims description 373
- 239000000126 substance Substances 0.000 claims description 312
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 claims description 283
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 claims description 283
- 238000000034 method Methods 0.000 claims description 146
- 102000004878 Gelsolin Human genes 0.000 claims description 137
- 108090001064 Gelsolin Proteins 0.000 claims description 137
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 69
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 69
- 239000003814 drug Substances 0.000 claims description 66
- 229940124597 therapeutic agent Drugs 0.000 claims description 60
- 230000000694 effects Effects 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 29
- 230000001225 therapeutic effect Effects 0.000 claims description 26
- 238000001514 detection method Methods 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 30
- 238000005259 measurement Methods 0.000 description 23
- 235000012000 cholesterol Nutrition 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 238000003745 diagnosis Methods 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 3
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 3
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 3
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- HVYWMOMLDIMFJA-IFAPJKRJSA-N Cholesterol_d7 Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])[C@@]1(C)CC2 HVYWMOMLDIMFJA-IFAPJKRJSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000002098 selective ion monitoring Methods 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- 108010026424 tau Proteins Proteins 0.000 description 2
- 102000013498 tau Proteins Human genes 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000022099 Alzheimer disease 2 Diseases 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/20—Oxygen containing
- Y10T436/203332—Hydroxyl containing
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012539625A JP5695075B2 (ja) | 2010-10-20 | 2011-06-23 | アルツハイマー病又は軽度認知症のバイオマーカー |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010235203 | 2010-10-20 | ||
| JP2010235203 | 2010-10-20 | ||
| US201061424885P | 2010-12-20 | 2010-12-20 | |
| JP2010282938 | 2010-12-20 | ||
| JP2010282938 | 2010-12-20 | ||
| US61/424885 | 2010-12-20 | ||
| PCT/JP2011/064487 WO2012053255A1 (ja) | 2010-10-20 | 2011-06-23 | アルツハイマー病又は軽度認知症のバイオマーカー |
| JP2012539625A JP5695075B2 (ja) | 2010-10-20 | 2011-06-23 | アルツハイマー病又は軽度認知症のバイオマーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2012053255A1 JPWO2012053255A1 (ja) | 2014-02-24 |
| JP5695075B2 true JP5695075B2 (ja) | 2015-04-01 |
Family
ID=45974981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012539625A Expired - Fee Related JP5695075B2 (ja) | 2010-10-20 | 2011-06-23 | アルツハイマー病又は軽度認知症のバイオマーカー |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9581604B2 (https=) |
| EP (1) | EP2631646B1 (https=) |
| JP (1) | JP5695075B2 (https=) |
| AU (1) | AU2011319319B2 (https=) |
| BR (1) | BR112013009592A2 (https=) |
| CA (1) | CA2814385C (https=) |
| IN (1) | IN2013CN02996A (https=) |
| NZ (1) | NZ609324A (https=) |
| RU (1) | RU2563987C2 (https=) |
| WO (1) | WO2012053255A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201212084D0 (en) * | 2012-07-06 | 2012-08-22 | Randox Lab Ltd | Tropomyosin isoforms related to alzheimers disease and mild cognitive impairment |
| EP3267200A4 (en) * | 2015-03-06 | 2018-08-22 | Niigata University | Biomarker of dementia with lewy bodies |
| ES2657414T3 (es) * | 2015-11-20 | 2018-03-05 | Geroa Diagnostics, S.L | Uso de la lactoferrina en el diagnóstico o el pronóstico de la enfermedad de Alzheimer |
| CN114410774A (zh) * | 2022-02-17 | 2022-04-29 | 杭州怡健医疗科技有限公司 | 一种应用于阿尔茨海默氏症的患病风险评估方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003088811A2 (en) * | 2002-04-16 | 2003-10-30 | The Brigham And Women's Hospital, Inc. | Gelsolin as a prognostic marker of artherosclerotic diseases |
| JPWO2007097461A1 (ja) * | 2006-02-27 | 2009-07-16 | 国立大学法人 熊本大学 | Ｃ型肝炎治療用抗体 |
| US7645748B2 (en) * | 2006-04-03 | 2010-01-12 | Forbes Medi-Tech Inc. | Sterol/stanol phosphorylnitroderivatives and use thereof |
| RU2356058C2 (ru) * | 2006-11-27 | 2009-05-20 | Александр Васильевич Мальцев | Способ диагностики амилоидоза при болезни альцгеймера и комплект средств для его осуществления |
-
2011
- 2011-06-23 CA CA2814385A patent/CA2814385C/en not_active Expired - Fee Related
- 2011-06-23 BR BR112013009592A patent/BR112013009592A2/pt not_active Application Discontinuation
- 2011-06-23 AU AU2011319319A patent/AU2011319319B2/en not_active Ceased
- 2011-06-23 US US13/880,475 patent/US9581604B2/en not_active Expired - Fee Related
- 2011-06-23 JP JP2012539625A patent/JP5695075B2/ja not_active Expired - Fee Related
- 2011-06-23 IN IN2996CHN2013 patent/IN2013CN02996A/en unknown
- 2011-06-23 RU RU2013122853/15A patent/RU2563987C2/ru not_active IP Right Cessation
- 2011-06-23 WO PCT/JP2011/064487 patent/WO2012053255A1/ja not_active Ceased
- 2011-06-23 EP EP11834097.5A patent/EP2631646B1/en active Active
- 2011-06-23 NZ NZ609324A patent/NZ609324A/en not_active IP Right Cessation
Non-Patent Citations (6)
| Title |
|---|
| JPN6014029296; Ｂｉｏｃｈｉｍ Ｂｉｏｐｈｙｓ Ａｃｔａ， ２０１０．０８， Ｖｏｌ．１８０１， Ｎｏ．８， Ｐａｇｅ．９４５-９５０ * |
| JPN6014029297; 日本臨床， ２００８， Ｖｏｌ．６６， 増刊号１， Ｐａｇｅ．２３２-２３６ * |
| JPN6014029298; 臨床神経，４８：４６７-４７５，２００８ * |
| JPN6014029300; Ｊ． Ａｌｚｈｅｉｍｅｒ'ｓ． Ｄｉｓ．， ２０１０， Ｖｏｌ．２１， Ｎｏ．２， Ｐａｇｅ．５８５-５９６ * |
| JPN6014029301; 日本老年医学会雑誌， １９９２， Ｖｏｌ．２９， Ｎｏ．７／８， Ｐａｇｅ．５５９-５６４ * |
| JPN6014029303; バイオメディカル分析科学シンポジウム講演要旨集， ２０１０．０７．２１， Ｖｏｌ．２３ｒｄ， Ｐａｇｅ．１９６-１９７ * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2814385C (en) | 2017-10-24 |
| WO2012053255A1 (ja) | 2012-04-26 |
| AU2011319319A1 (en) | 2013-05-02 |
| NZ609324A (en) | 2014-09-26 |
| EP2631646B1 (en) | 2016-10-19 |
| US20130266589A1 (en) | 2013-10-10 |
| BR112013009592A2 (pt) | 2016-07-12 |
| US9581604B2 (en) | 2017-02-28 |
| RU2013122853A (ru) | 2014-11-27 |
| CA2814385A1 (en) | 2012-04-26 |
| EP2631646A1 (en) | 2013-08-28 |
| IN2013CN02996A (https=) | 2015-08-14 |
| EP2631646A4 (en) | 2014-05-07 |
| AU2011319319B2 (en) | 2015-07-30 |
| RU2563987C2 (ru) | 2015-09-27 |
| JPWO2012053255A1 (ja) | 2014-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6021187B2 (ja) | 自閉症の代謝バイオマーカー | |
| US20200173979A1 (en) | Trimethylamine compounds as risk predictors of cardiovascular disease | |
| Begcevic et al. | Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer’s disease and age-matched control brains | |
| Reale et al. | Saliva, an easily accessible fluid as diagnostic tool and potent stem cell source for Alzheimer’s Disease: Present and future applications | |
| US20140357525A1 (en) | Markers for alzheimer's disease and mild cognitive impairment and methods of using the same | |
| Stefani et al. | AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis | |
| EP3190413A1 (en) | Method for predicting depression treatment drug alternatives | |
| KR20170061704A (ko) | 난소암을 검출하는 방법 | |
| JP6569919B2 (ja) | レビー小体型認知症のバイオマーカー | |
| JP5695075B2 (ja) | アルツハイマー病又は軽度認知症のバイオマーカー | |
| Li et al. | Cerebrospinal fluid ubiquitin C-terminal hydrolase as a novel marker of neuronal damage after epileptic seizure | |
| Öhrfelt et al. | Screening for new biomarkers for subcortical vascular dementia and Alzheimer’s disease | |
| Sbriscia et al. | miR-132–3p is down-regulated in plasma and CD171+ extracellular vesicles isolated from patients with mild Alzheimer’s disease | |
| EP3707513B1 (en) | Method for establishing the presence and progression of neurodegenerative disease | |
| KR102177280B1 (ko) | 호모시스테인 설핀산 또는 시스테인산을 포함하는 급성심근경색 진단용 바이오마커 조성물 | |
| Korkmaz et al. | Relationship Between BDNF and LPS Levels in the Blood of Patients with Different Neurological Diseases: A Small Cohort Study | |
| KR101990681B1 (ko) | 편두통 진단용 바이오마커 및 상기 바이오마커를 이용한 편두통 진단방법 | |
| Kovalenko et al. | Non-Invasive Biomarkers for the Early Diagnosis of Alzheimer’s Disease in Body Fluids | |
| EP3301113A1 (en) | Melanotransferrin for use in the diagnosis of parkinson's disease | |
| KR20260006588A (ko) | 경도인지장애 및 알츠하이머병에 대한 단백질 마커 | |
| Youh et al. | Biomarkers and Applications in Alzheimer's Disease | |
| WO2025040574A1 (en) | Methods for predicting cognitive decline in a subject | |
| CN115754067A (zh) | 肉豆蔻酰溶血磷脂酰胆碱的检测试剂在制备诊断cap的产品中的用途 | |
| CN121141919A (zh) | 一种血栓性抗磷脂综合征相关的标志物及其应用 | |
| EP2893042A2 (en) | Diagnostic testing in dementia and methods related thereto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140715 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140811 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150127 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150205 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5695075 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |